Skip to main content
. Author manuscript; available in PMC: 2018 May 1.
Published in final edited form as: Mol Cancer Res. 2017 May;15(5):521–531. doi: 10.1158/1541-7786.MCR-16-0315

Figure 1.

Figure 1

YM155 synergizes with high-androgen therapy to suppress prostate cancer viability. A) Design of high-throughput screen in LNCaP grown in 10% FBS media supplemented with either 1nM R1881, 10uM Enzalutamide (ENZ), or DMSO. B) Average CellTiter-Glo luciferase signal (viability) for all control wells on drug screen 96 hours post cell seeding. C) Inhibitory concentration for 50% viability (IC50) plotted for various doses of R1881 and D) enzalutamide (ENZ).